Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1No longer available 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Hematologic Neoplasms 2Cholangiocarcinoma 2Noonan Syndrome 6 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Granuloma, Plasma Cell 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

fludarabine phosphate 7Mycophenolic Acid 6Brentuximab Vedotin 6Whole-Body Irradiation 5Tacrolimus 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 5Bortezomib 5Methotrexate 4Antilymphocyte Serum 4tanespimycin 3Radiotherapy 3Lenalidomide 3Filgrastim 3Etoposide 3Dasatinib 3Cyclosporine 3Cord Blood Stem Cell Transplantation 3merphos 2Vorinostat 2Vincristine 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cyproheptadine 2Carboplatin 2Busulfan 2romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large-Cell, Anaplastic × ceritinib × Clear all
NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡